La description :crossject developed zeneo®, a world-leading needle-free injection platform, designed to improve patients’ safety and comfort and to enable a better observance of treatments. needleless free injection ...
Geo IP vous fournit comme la latitude, la longitude et l'ISP (Internet Service Provider) etc. informations.
Notre service GeoIP a trouvé l'hôte crossject.com.Actuellement, hébergé dans France et son fournisseur de services est Orange S.A. .
Les informations d'en-tête HTTP font partie du protocole HTTP que le navigateur d'un utilisateur envoie à appelé Apache contenant les détails de ce que le navigateur veut et acceptera de nouveau du serveur Web.
MX preference = 10, mail exchanger = mail.crossject.com.
HtmlToText
skip to main content toggle navigation drupal main navigation en about crossject who we are governance partners our news r&d zeneo® products zeneo®: needle-free technology pipeline zeneo® sumatriptan zeneo® adrenaline zeneo® hydrocortisone zeneo® midazolam zeneo® naloxone zeneo® methotrexate zeneo® apomorphine zeneo® terbutaline finances profile analyst coverage financial releases main navigation 2 en press resources press releases image bank careers working at crossject our careers available position and applications contact fr en zeneo®, a unique device worldwide lien crossject: the expert in needle-free injection lien dare, persevere and innovate, to save lives simply google previous next crossject is revolutionizing needle free injection paragraphes colonne 1 crossject is revolutionizing the administration of well-established, clinically-proven treatments and bringing unprecedented advantages to patients with its innovative, needle-free auto-injector zeneo® . the prefilled, single-use device propels the medicine through the skin in less than a tenth of a second . crossject currently has eight zeneo® solutions in advanced stages of development, seven of which are for emergency situations. our news image de l'actualité crossject will be attending the 2018 bio international convention in boston résumé de l'actualité crossject coo olivier giré will be attending the 2018 bio one-on-one partnering™ in boston from june 3th to 6th. image de l'actualité zeneo® midazolam earns the orphan drug designation résumé de l'actualité the fda has granted orphan drug designation to zeneo® midazolam for the treatment of status epileptics. image financial news: crossject announces the principle of the free issue and allotment of warrants to the shareholders and new € 2.5 million convertible bond menu pied de page news legal information sitemap privacy terms cookies follow us
Whois est un protocole qui permet d'accéder aux informations d'enregistrement.Vous pouvez atteindre quand le site Web a été enregistré, quand il va expirer, quelles sont les coordonnées du site avec les informations suivantes. En un mot, il comprend ces informations;
Domain Name: CROSSJECT.COM
Registry Domain ID: 71496760_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.gandi.net
Registrar URL: http://www.gandi.net
Updated Date: 2015-04-29T12:22:54Z
Creation Date: 2001-05-29T14:36:00Z
Registry Expiry Date: 2018-05-29T14:36:00Z
Registrar: Gandi SAS
Registrar IANA ID: 81
Registrar Abuse Contact Email: abuse@support.gandi.net
Registrar Abuse Contact Phone: +33.170377661
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Name Server: DNS1.ALWAYSDATA.COM
Name Server: DNS2.ALWAYSDATA.COM
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2017-12-02T20:21:10Z <<<
For more information on Whois status codes, please visit https://icann.org/epp
NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.
TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.
The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.
REGISTRAR Gandi SAS
SERVERS
SERVER com.whois-servers.net
ARGS domain =crossject.com
PORT 43
TYPE domain RegrInfo DOMAIN
NAME crossject.com
CHANGED 2015-04-29
CREATED 2001-05-29
STATUS clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Nous utilisons des cookies pour personnaliser votre expérience sur notre site. En poursuivant votre navigation, vous acceptez cette utilisation. Apprendre encore plus
crossject.com rapport :
Visitez le site